MiMedx Accounts Payable vs Other Stockholder Equity Analysis

MDXG Stock  USD 9.59  0.04  0.42%   
MiMedx financial indicator trend analysis is infinitely more than just investigating MiMedx Group recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MiMedx Group is a good investment. Please check the relationship between MiMedx Accounts Payable and its Other Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Accounts Payable vs Other Stockholder Equity

Accounts Payable vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MiMedx Group Accounts Payable account and Other Stockholder Equity. At this time, the significance of the direction appears to have weak relationship.
The correlation between MiMedx's Accounts Payable and Other Stockholder Equity is 0.39. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of MiMedx Group, assuming nothing else is changed. The correlation between historical values of MiMedx's Accounts Payable and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of MiMedx Group are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Accounts Payable i.e., MiMedx's Accounts Payable and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.39
Relationship DirectionPositive 
Relationship StrengthVery Weak

Accounts Payable

An accounting item on the balance sheet that represents MiMedx obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of MiMedx Group are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Stockholder Equity

Most indicators from MiMedx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MiMedx Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, MiMedx's Enterprise Value Multiple is most likely to increase significantly in the upcoming years. The MiMedx's current Enterprise Value is estimated to increase to about 1 B, while Selling General Administrative is projected to decrease to roughly 123.2 M.
 2021 2023 2024 (projected)
Non Recurring53K47.7K45.3K
Reconciled Depreciation5.2M3.6M4.6M

MiMedx fundamental ratios Correlations

0.450.680.610.49-0.61-0.570.560.880.81-0.040.880.540.720.510.60.830.640.97-0.010.740.60.690.870.170.8
0.450.590.630.37-0.81-0.060.610.360.440.490.380.690.720.010.40.380.220.410.220.710.70.490.320.320.25
0.680.590.920.09-0.6-0.360.850.610.660.440.60.60.630.440.730.390.690.620.00.660.910.910.630.590.32
0.610.630.920.1-0.64-0.310.960.540.650.550.530.60.610.30.670.370.60.530.020.650.970.910.650.720.19
0.490.370.090.1-0.38-0.090.210.160.660.080.170.210.45-0.46-0.210.77-0.350.370.410.420.080.030.56-0.070.48
-0.61-0.81-0.6-0.64-0.380.51-0.58-0.68-0.45-0.29-0.69-0.62-0.64-0.15-0.35-0.62-0.35-0.61-0.05-0.68-0.67-0.49-0.52-0.28-0.31
-0.57-0.06-0.36-0.31-0.090.51-0.2-0.77-0.340.13-0.76-0.37-0.43-0.48-0.36-0.65-0.51-0.610.25-0.49-0.27-0.36-0.55-0.16-0.29
0.560.610.850.960.21-0.58-0.20.410.680.550.40.590.580.130.530.390.440.460.170.60.920.840.650.730.17
0.880.360.610.540.16-0.68-0.770.410.53-0.131.00.480.60.710.680.690.780.93-0.320.650.530.610.730.170.61
0.810.440.660.650.66-0.45-0.340.680.530.40.520.510.670.080.480.780.290.650.210.680.630.710.880.490.49
-0.040.490.440.550.08-0.290.130.55-0.130.4-0.130.320.25-0.320.320.0-0.08-0.210.060.240.580.430.20.84-0.48
0.880.380.60.530.17-0.69-0.760.41.00.52-0.130.490.610.70.670.70.770.93-0.310.660.520.590.720.150.62
0.540.690.60.60.21-0.62-0.370.590.480.510.320.490.880.270.50.480.430.490.40.860.60.570.350.370.3
0.720.720.630.610.45-0.64-0.430.580.60.670.250.610.880.260.560.690.430.660.230.990.580.620.570.30.49
0.510.010.440.3-0.46-0.15-0.480.130.710.08-0.320.70.270.260.730.070.940.63-0.420.30.330.50.23-0.010.44
0.60.40.730.67-0.21-0.35-0.360.530.680.480.320.670.50.560.730.230.850.59-0.440.590.690.790.520.550.24
0.830.380.390.370.77-0.62-0.650.390.690.780.00.70.480.690.070.230.190.760.120.710.330.380.840.130.61
0.640.220.690.6-0.35-0.35-0.510.440.780.29-0.080.770.430.430.940.850.190.71-0.350.470.610.740.420.240.44
0.970.410.620.530.37-0.61-0.610.460.930.65-0.210.930.490.660.630.590.760.71-0.10.680.530.610.770.020.84
-0.010.220.00.020.41-0.050.250.17-0.320.210.06-0.310.40.23-0.42-0.440.12-0.35-0.10.160.02-0.01-0.13-0.140.16
0.740.710.660.650.42-0.68-0.490.60.650.680.240.660.860.990.30.590.710.470.680.160.610.650.610.340.47
0.60.70.910.970.08-0.67-0.270.920.530.630.580.520.60.580.330.690.330.610.530.020.610.880.580.670.21
0.690.490.910.910.03-0.49-0.360.840.610.710.430.590.570.620.50.790.380.740.61-0.010.650.880.670.650.28
0.870.320.630.650.56-0.52-0.550.650.730.880.20.720.350.570.230.520.840.420.77-0.130.610.580.670.460.5
0.170.320.590.72-0.07-0.28-0.160.730.170.490.840.150.370.3-0.010.550.130.240.02-0.140.340.670.650.46-0.41
0.80.250.320.190.48-0.31-0.290.170.610.49-0.480.620.30.490.440.240.610.440.840.160.470.210.280.5-0.41
Click cells to compare fundamentals

MiMedx Account Relationship Matchups

MiMedx fundamental ratios Accounts

201920202021202220232024 (projected)
Other Current Liab56.7M50.4M35.0M35.1M37.0M22.9M
Common Stock Shares Outstanding105.6M108.3M110.4M112.9M146.0M94.7M
Other Liab621K3.8M4.9M2.3M2.1M2.6M
Net Tangible Assets6.6M91.4M(25.3M)(43.8M)(39.4M)(37.5M)
Other Assets443K375K186K148K133.2K126.5K
Property Plant Equipment15.7M11.4M13.9M11.3M12.9M10.9M

Currently Active Assets on Macroaxis

When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.1)
Earnings Share
0.57
Revenue Per Share
2.447
Quarterly Revenue Growth
0.029
Return On Assets
0.1838
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.